Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Go back to Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases| Diversified Corporate Resources, Inc. (NASDAQ: IRD) | Delayed: 4.05 -0.07 (1.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.12 | 52 Week High | $0.02 | |||
| Open | $4.16 | 52 Week Low | $0.02 | |||
| Day High | $4.33 | P/E | N/A | |||
| Day Low | $4.02 | EPS | $0.00 | |||
| Volume | 1,052,694 | |||||
